association of the beta-1 adrenergic receptor carboxyl terminal variants with left ventricular hypertrophy among diabetic and non-diabetic survivors of acute myocardial infarction协会的beta 1肾上腺素能受体羧基末端变异与左心室肥大在糖尿病和非糖尿病急性心肌梗死的幸存者.pdfVIP

Hakalahti et al. Cardiovascular Diabetology 2010, 9:42 CARDIO /content/9/1/42 VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Association of the beta-1 adrenergic receptor carboxyl terminal variants with left ventricular hypertrophy among diabetic and non-diabetic survivors of acute myocardial infarction 1* 2 3 3 3 1 Anna E Hakalahti , Jari M Tapanainen , Juhani M Junttila , Kari S Kaikkonen , Heikki V Huikuri , Ulla E Petäjä-Repo Abstract Background: The beta-1 adrenergic receptor (b AR) plays a fundamental role in the regulation of cardiovascular 1 functions. It carries a nonsynonymous single nucleotide polymorphism in its carboxyl terminal tail (Arg389Gly), which has been shown to associate with various echocardiographic parameters linked to left ventricular hypertrophy (LVH). Diabetes mellitus (DM), on the other hand, represents a risk factor for LVH. We investigated the possible association between the Arg389Gly polymorphism and LVH among non-diabetic and diabetic acute myocardial infarction (AMI) survivors. Methods: The study population consisted of 452 AMI survivors, 20.6% of whom had diagnosed DM. Left ventricular parameters were measured with two-dimensional guided M-mode echocardiography 2-7 days after AMI, and the Arg389Gly polymorphism was determined using a polymerase chain reaction-restriction fragment length polymorphism assay. Results: The Arg389 homo